Jul 23, 2026 | Blog
The final participant visit is usually treated as the end of a clinical trial. For Africa’s health-product economy, it should be a handover point: the moment when evidence begins to inform regulatory approval, manufacturing, procurement and delivery. African...
Jul 17, 2026 | Blog
A clinical trial can leave behind a valuable dataset, a published paper and a team with new experience. It can also leave behind an empty office, expired service contracts, underused equipment and research professionals searching for the next grant. The difference is...
Jul 9, 2026 | Blog
In clinical research, few words carry more operational risk than “ready.” A site may be described as ready when a Research Ethics Committee or Institutional Review Board has approved the protocol. A network may be described as ready when a master agreement is in...
Jul 2, 2026 | Blog
For decades, discussions about equity in global clinical research have often focused on the terms of partnership, who owns the data, who leads publications, who holds intellectual property, and who captures the economic value created by research. These are important...
Jun 25, 2026 | Blog
Most scaling plans for clinical research in Africa describe expansion. Fewer describe integration. Expansion adds sites, countries, investigators, and trials. Integration is the harder work of making those additions function as a single operational system. The...
May 29, 2026 | Blog
When a clinical trial in Africa stalls, the explanation is often immediate: “regulatory delay.” It is a convenient phrase. It is also too often an incomplete one. “Regulatory delay” can mean many different things. It can mean a regulator took longer than expected. It...
